



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/087,273

03/01/2002

John R. Gordon

4616-62340 6 a 4 30

CONFIRMATION NO. 3115

FORMALITIES LETTER

OC000000007883592

KLARQUIST SPARKMAN, LLP One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, OR 97204

Date Mailed: 04/17/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(I) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu



For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

SI.S:lam 8/19/02 4616-62430 1353

PATENT
Attorney Reference Number 4616-62430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

h re application of: Gordon et al.

Application No. 10/087,273

Filed: March 1, 2002

For: HIGH-AFF

HIGH-AFFINITY ANTAGONISTS OF

ELR-CXC CHEMOKINES

Examiner: Not yet assigned

Date: August 19, 2002

Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on August 19, 2002, as First Class Mail in an envelope addressed to:

BOX MISSING PARTS, COMMISSIONER FOR PATENTS,

WASHINGTON D.C. 20231.

Altorney for Applicant

MISSING PARTS TRANSMITTAL LETTER

U.S. Patent and Trademark Office Box Sequence, PO Box 2327 Arlington, VA 22202

Enclosed for filing in the application referenced above are the following:

\boxtimes	Copy of Notice to File Missing Parts of ApplicationFiling Date Granted
$\overline{\boxtimes}$	Assignment and Recordal Fee of \$40.00
	Combined Declaration and Power of Attorney
$\overline{\boxtimes}$	Sequence Listing
	Statement of Compliance
	Paper Copy (identical to computer copy), 3 pages.
	Computer readable disk.
\boxtimes	Surcharge for Late Filing of Fee or Oath or Declaration
\boxtimes	2-month extension fee of \$400.00
\boxtimes	Letter to Official Draftsperson
\boxtimes	7 sheets of formal drawings

Applicants petition for an extension of time for 2 month(s). If an additional extension of time is required please consider this a petition therefor.

A check in the amount of \$670.00 to cover the above-listed fees

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.

03/25/E002 KMUHRMH1 00000075 10087273

01 FU8/15

400.00 02

Regina Refs 08/26/2002 NACHARM1 0020172500 00/10024550 Nace/Rubbers10087273 FDs 704 \$100.00 CR Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

y Mma

Donald L. Stephens Jr.

Registration No. 34,022

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc: Docketing

Attorney Reference Number: 4616-62430

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gordon et al.

Art Unit: 1645

Application No.: 10/087,273

Filed: March 1, 2002

For: HIGH-AFFINITY ANTAGONISTS OF

ELR-CXC CHEMOKINES

Examiner: Not yet assigned.

Date: August 19, 2002

U.S. Patent and Trademark Office Box Sequence, PO Box 2327 Arlington, VA 22202

LETTER TO THE OFFICIAL DRAFTSPERSON

Attached are 7 sheets of formal drawings for this application, with each sheet indicating the title, inventors' names, and application number on the front of each sheet and centered within the top margin.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Donald L. Stephens Jr.

Registration No. 34,022

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391

Facsimile: (503) 228-9446



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gordon et al.

Art Unit: 1645

Application No. 10/087,273

Filed: March 1, 2002

For: HIGH-AFFINITY ANTAGONISTS OF

ELR-CXC CHEMOKINES

Examiner: Not yet assigned.

Date: August 19, 2002

STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)

U.S. Patent and Trademark Office Box Sequence, PO Box 2327 Arlington, VA 22202

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing." No new matter has been added.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Donald L. Stephens Jr.

Registration No. 34,022

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446